Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.174.62 ]

🍽️ gefitinib,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Anticancer Effects: Gefitinib is classified as a tyrosine kinase inhibitor (TKI) that works by blocking the activity of the EGFR protein, which is involved in the growth and spread of cancer cells. By inhibiting EGFR signaling, gefitinib helps to slow down or stop the growth of cancer cells in the lungs.

  2. EGFR Mutation: Gefitinib is most effective in patients with NSCLC who have EGFR mutations. These mutations make cancer cells more dependent on EGFR signaling for their growth and survival, making them more susceptible to gefitinib's inhibitory effects.

  3. Improvement in Symptoms: Gefitinib treatment can lead to improvements in symptoms such as coughing, shortness of breath, and chest pain in patients with NSCLC. It may also improve overall quality of life by slowing disease progression.

  4. Response Rate: In clinical trials, gefitinib has been shown to produce tumor responses in a subset of patients with NSCLC, including partial and complete responses. However, not all patients will respond to treatment, and response rates may vary depending on factors such as EGFR mutation status and disease stage.

  5. Adverse Effects: Common side effects of gefitinib treatment include diarrhea, skin rash or acne, dry skin, nausea, vomiting, loss of appetite, fatigue, and nail changes. Most side effects are mild to moderate in severity and can often be managed with supportive care or dose adjustments.

  6. Interstitial Lung Disease (ILD): Gefitinib has been associated with the development of ILD, a potentially serious side effect characterized by inflammation and scarring of lung tissue. Patients experiencing new or worsening respiratory symptoms such as cough, difficulty breathing, or fever should seek medical attention promptly.

  7. Liver Toxicity: Gefitinib can affect liver function, leading to elevated liver enzyme levels in some patients. Regular monitoring of liver function tests is recommended during gefitinib treatment to detect and manage liver toxicity.

  8. Cardiovascular Effects: Rarely, gefitinib treatment may be associated with cardiovascular side effects such as QT prolongation (a heart rhythm disorder) and thromboembolism (blood clots). Patients with preexisting cardiovascular risk factors should be monitored closely during treatment.

  9. Drug Interactions: Gefitinib may interact with other medications, including certain antibiotics, antifungals, and anticonvulsants, which can affect its metabolism and efficacy. Patients should inform their healthcare provider about all medications they are taking before starting gefitinib treatment.

  10. Pregnancy and Breastfeeding: Gefitinib can cause fetal harm if used during pregnancy, and women of childbearing potential should use effective contraception during treatment and for a period afterward. Breastfeeding is not recommended during gefitinib treatment due to the potential for adverse effects on the infant.

  11. Patient Counseling: Patients receiving gefitinib should be counseled about the importance of adherence to treatment, management of side effects, and the need for regular medical monitoring. They should also be educated about signs and symptoms of potential complications such as ILD.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of gefitinib,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by gefitinib,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Blautia genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Coprococcus genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Segatella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Collinsella genus Decreases 👪 Source Study proinflammatory
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Blautia obeum species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
[Ruminococcus] gnavus species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Lactonifactor longoviformis species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Anaerosporobacter mobilis species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of gefitinib,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 2.4 0.5 3.8
Age-Related Macular Degeneration and Glaucoma 0.9 0.1 8
Allergic Rhinitis (Hay Fever) 1.2 1.2
Allergies 2.8 1.9 0.47
Allergy to milk products 1.1 0.1 10
Alopecia (Hair Loss) 1.2 1.2
Alzheimer's disease 2.4 6.9 -1.88
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.7 0.5 4.4
Ankylosing spondylitis 1.8 1.8 0
Anorexia Nervosa 0.1 3 -29
Antiphospholipid syndrome (APS) 1.5 1.5
Asthma 0.3 0.7 -1.33
Atherosclerosis 0.5 1.7 -2.4
Atrial fibrillation 3.3 0.9 2.67
Autism 6.7 7.2 -0.07
Bipolar Disorder 0.8 1.4 -0.75
Brain Trauma 0 0.7 0
Carcinoma 1.9 1.9 0
Celiac Disease 0.6 2.3 -2.83
Cerebral Palsy 0.3 1.7 -4.67
Chronic Fatigue Syndrome 4 4.8 -0.2
Chronic Kidney Disease 1.9 2.5 -0.32
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 1.4 -1.4
Chronic Urticaria (Hives) 0.3 1.3 -3.33
Coagulation / Micro clot triggering bacteria 0.1 1.4 -13
Colorectal Cancer 2 0.5 3
Constipation 1.1 0.9 0.22
Coronary artery disease 1.6 1 0.6
COVID-19 5 11.5 -1.3
Crohn's Disease 5 6 -0.2
cystic fibrosis 0.7 -0.7
deep vein thrombosis 0.9 -0.9
Depression 5.8 6.1 -0.05
Eczema 0.6 1 -0.67
Endometriosis 1.8 1 0.8
Epilepsy 1.5 0.8 0.88
Fibromyalgia 1.8 2.8 -0.56
Functional constipation / chronic idiopathic constipation 3.9 3.8 0.03
gallstone disease (gsd) 1.9 0.4 3.75
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1 1 0
Generalized anxiety disorder 1.1 1.1 0
giant cell arteritis 0.3 -0.3
Gout 0.5 -0.5
Graves' disease 0.4 1.5 -2.75
Halitosis 0.2 0.2
Hashimoto's thyroiditis 2.7 0.2 12.5
Histamine Issues,Mast Cell Issue, DAO Insufficiency 1.9 1.4 0.36
hypercholesterolemia (High Cholesterol) 0.3 0.3
hyperglycemia 0.8 -0.8
Hyperlipidemia (High Blood Fats) 0 0 0
hypersomnia 0.5 -0.5
hypertension (High Blood Pressure 0.9 3.1 -2.44
Hypothyroidism 1 -1
Hypoxia 0.3 0.3
IgA nephropathy (IgAN) 3.8 -3.8
Inflammatory Bowel Disease 1.5 8 -4.33
Insomnia 0.7 1.2 -0.71
Intelligence 1.5 0.6 1.5
Intracranial aneurysms 1.3 0 0
Irritable Bowel Syndrome 2 2.5 -0.25
Liver Cirrhosis 3.1 2.5 0.24
Long COVID 5.2 7.4 -0.42
Low bone mineral density 1.4 -1.4
Lung Cancer 1.5 -1.5
ME/CFS with IBS 1.3 3.2 -1.46
ME/CFS without IBS 1 1.9 -0.9
Menopause 0.2 0.2
Metabolic Syndrome 4.5 5.5 -0.22
Mood Disorders 7.4 6.1 0.21
multiple chemical sensitivity [MCS] 0.5 -0.5
Multiple Sclerosis 1.6 5.7 -2.56
Multiple system atrophy (MSA) 0.7 1 -0.43
Neuropathy (all types) 0.5 0.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2 4.2 -1.1
Obesity 6.5 3.3 0.97
obsessive-compulsive disorder 4.7 4.4 0.07
Osteoarthritis 1.1 0.5 1.2
Osteoporosis 1.1 0.7 0.57
Parkinson's Disease 0.6 4.6 -6.67
Polycystic ovary syndrome 2 1.7 0.18
Postural orthostatic tachycardia syndrome 0.3 0.5 -0.67
Premenstrual dysphoric disorder 0.5 0.1 4
primary biliary cholangitis 0.5 0.7 -0.4
Psoriasis 3.1 2.1 0.48
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4.6 2.7 0.7
Rosacea 1.5 0.7 1.14
Schizophrenia 3.5 2.2 0.59
scoliosis 0.5 1.5 -2
Sjögren syndrome 1.2 2.5 -1.08
Sleep Apnea 1.5 1.7 -0.13
Stress / posttraumatic stress disorder 1.6 1.2 0.33
Systemic Lupus Erythematosus 2.6 1.9 0.37
Tic Disorder 0.9 1.1 -0.22
Tourette syndrome 0.2 -0.2
Type 1 Diabetes 3 1.6 0.88
Type 2 Diabetes 4.5 5.2 -0.16
Ulcerative colitis 2 3.4 -0.7
Unhealthy Ageing 4.3 1.9 1.26

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant. [35.174.62 ]